Purpose of investigation: To evaluate chemotherapy with concomitant radiotherapy (RT) in “high risk” endometrial cancer (EC) patients. Furthermore to develop a new algorithm for management and treatment. Materials and Methods: The study included 182 Stage I endometrioid EC patients who underwent definitive surgery after a first treatment. Stage, grade, ploidy DNA index, lymphovascular space involvement (LVSI), tumor diameter (TD), and p53 were considered to identify “high-risk” patients. Twenty-seven women received adjuvant concomitant chemoradiation (CR). Toxicity related to the CR treatment, disease free interval (DFI), and status of the patients were considered. Results: Twenty-seven patients according to the present algorithm treatment were considered at “high risk”. Median follow up was 43 months (range 16-68). Twenty-five (92%) patients completed CR treatment. Overall, grade 3/4 hematological toxicity was 18% while gastrointestinal toxicity was 15%. Four patients relapsed with a five-year rate of 14% of recurrences. Conclusions: Adjuvant concomitant CR is well tolerated and is a feasible regimen in “high risk” patients. The authors’ new algorithm treatment could be used for management and further clinical studies.
Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers
Vitale, S. G.;
2016-01-01
Abstract
Purpose of investigation: To evaluate chemotherapy with concomitant radiotherapy (RT) in “high risk” endometrial cancer (EC) patients. Furthermore to develop a new algorithm for management and treatment. Materials and Methods: The study included 182 Stage I endometrioid EC patients who underwent definitive surgery after a first treatment. Stage, grade, ploidy DNA index, lymphovascular space involvement (LVSI), tumor diameter (TD), and p53 were considered to identify “high-risk” patients. Twenty-seven women received adjuvant concomitant chemoradiation (CR). Toxicity related to the CR treatment, disease free interval (DFI), and status of the patients were considered. Results: Twenty-seven patients according to the present algorithm treatment were considered at “high risk”. Median follow up was 43 months (range 16-68). Twenty-five (92%) patients completed CR treatment. Overall, grade 3/4 hematological toxicity was 18% while gastrointestinal toxicity was 15%. Four patients relapsed with a five-year rate of 14% of recurrences. Conclusions: Adjuvant concomitant CR is well tolerated and is a feasible regimen in “high risk” patients. The authors’ new algorithm treatment could be used for management and further clinical studies.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
